Veru Reports Positive Phase 2 Clinical Trial Results for Enobosarm, Selective Androgen Receptor Targeting Agent, for Endocrine Resistant Metastatic Breast Cancer

Stock Information for Veru Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Veru Inc.

Veru Announces Date of 2024 Annual Meeting of Shareholders
Veru Reschedules Annual Meeting of Shareholders
Veru Announces the Appointment of Louis Aronne MD as Chief Medical Advisor for its Enobosarm Program for High Quality Weight Loss
Veru Announces New Scientific Advisory Board for its Enobosarm Program for High Quality Weight Loss
Veru Reports Fiscal 2024 First Quarter Financial Highlights
Veru Announces FDA Clearance of IND Application to Initiate Phase 2b Clinical Trial with Enobosarm to Treat Muscle Loss Associated with Weight Loss Drugs
Veru to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
Veru to Report Fiscal 2024 First Quarter Financial Results on February 8, 2024

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.